Pulmonary abnormalities in obligate heterozygotes for cystic fibrosis

PAMELA B DAVIS, KATHRYN VARGO

From the Department of Pediatrics, Case Western Reserve University School of Medicine, and the Pulmonary Division, Veteran's Administration Medical Center, Cleveland, Ohio, USA

ABSTRACT Parents of children with cystic fibrosis have been reported to have a high prevalence of increased airway reactivity, but these studies were done in a select young, healthy, symptomless population. In the present study respiratory symptoms were examined in 315 unselected parents of children with cystic fibrosis and 162 parents of children with congenital heart disease (controls). The cardinal symptom of airway reactivity, wheezing, was somewhat more prevalent in cystic fibrosis parents than in controls, but for most subgroups this increased prevalence did not reach statistical significance. Among those who had never smoked, 38% of obligate heterozygotes for cystic fibrosis but only 25% of the controls reported wheezing (p < 0.05). The cystic fibrosis parents who had never smoked but reported wheezing had lower FEV₁ and FEF₂₅₋₇₅, expressed as a percentage of the predicted value, than control parents; and an appreciable portion of the variance in pulmonary function was contributed by the interaction of heterozygosity for cystic fibrosis with wheezing. For cystic fibrosis parents, but not controls, the complaint of wheezing significantly contributed to the prediction of pulmonary function (FEV₁ and FEF₂₅₋₇₅). In addition, parents of children with cystic fibrosis reported having lung disease before the age of 16 more than twice as frequently as control parents. Other respiratory complaints, including dyspnoea, cough, bronchitis, and hay fever, were as common in controls as in cystic fibrosis heterozygotes. These data are consistent with the hypothesis that heterozygosity for cystic fibrosis is associated with increased airway reactivity and its symptoms, and that the cystic fibrosis heterozygotes who manifest airway reactivity and its symptoms may be at risk for poor pulmonary function.

Cystic fibrosis, one of the most common genetic disorders of caucasians, is transmitted as an autosomal recessive trait; so the parents of a child with cystic fibrosis are obligate heterozygotes for the abnormal cystic fibrosis gene. At the molecular level heterozygotes almost certainly express the gene, though such expression may be masked or compensated for by other genes, and may be tissue specific. Detecting the expression of this gene in heterozygotes has, however, been difficult, even in the three tissues most consistently affected in homozygotes—the sweat gland, the pancreas, and the lung. Although, in most studies, the concentration of chloride in the sweat of obligate heterozygotes for cystic fibrosis was found to be greater than that of age matched controls,¹ there is considerable overlap, and sweat chloride concentration cannot be used to identify cystic fibrosis heterozygotes. Pancreatic function in cystic fibrosis heterozygotes has not been evaluated with sensitive tests, but neutral fat excretion is normal.² No pulmonary expression of the cystic fibrosis gene in heterozygotes has been clearly demonstrated.¹–⁸

Pulmonary abnormalities can, however, be provoked in cystic fibrosis heterozygotes by a non-specific bronchial irritant: about one third of symptomless, medication free, young heterozygotes for cystic fibrosis have increased bronchial reactivity to methacholine.⁹ To pursue this observation, we investigated respiratory symptoms in a large number of unselected individuals heterozygous for cystic fibrosis to test the hypothesis that, if non-specific airway reactivity is more prevalent in cystic fibrosis heterozygotes, then the cardinal symptom of airway reactivity—wheezing—will also be more prevalent. It seemed important to test whether airway reactivity...
and its symptom are indeed prevalent in cystic fibrosis heterozygotes as a group, for airway reactivity has been postulated to be a risk factor for development and progression of obstructive airways disease.\textsuperscript{10–13} If they have a high prevalence of airway reactivity, cystic fibrosis heterozygotes might constitute a sizable (4–5% of the white population) group at risk for airways obstruction.

**Methods**

**SUBJECTS**

Subjects gave consent to participate in this study, which was approved by the Institutional Review Board. Parents of children with cystic fibrosis were invited to participate as they accompanied their child on a clinic visit, visited the child in hospital, or volunteered to report on two special clinic days for the study. For all the children the diagnosis of cystic fibrosis was based on a sweat chloride concentration over 60 mEq/(mmol)/l and the presence of either pancreatic insufficiency or chronic obstructive pulmonary disease, or both. The only criteria for entry into the study for the parents were the biological relation to a child with cystic fibrosis and willingness to fill in the questionnaire and undergo spirometry. All available parents who visited the hospital during the study period participated (some, who visited only at weekends or late at night, were never contacted). The controls were the parents of children with congenital or acquired heart or circulatory disease attending the same ambulatory practice or admitted to the same hospital as the children with cystic fibrosis. The only entry criteria were the biological relationship to an ill child and willingness to participate. All parents available during the scheduled clinics we attended and all those in the wards when we visited were invited to participate; about one fifth declined, and no information on them is available. After data had been collected, for ease of analysis of pulmonary function test data, the study population was restricted to white subjects. This eliminated one heterozygote and seven control subjects, leaving 315 cystic fibrosis heterozygotes and 162 controls.

**QUESTIONNAIRE**

The ALA-DLD-78 questionnaire (basic version) was self administered. When help was requested, it was given in accordance with the directions of the epidemiology standardisation project.\textsuperscript{14} In addition, the diagnosis of the child in question was asked. Results were scored by hand and entered into DATA-TRIEVE, a database management program for the PDP 11/45 computer.

**SPIROMETRY**

Spirometers were performed on a Collins 8 L Survey Spirometer according to the methods set out in the epidemiology standardisation project.\textsuperscript{14} Subjects stood and wore noseclips. Each subject recorded at least three acceptable spiromgrams, two within 5% of each other for FVC, and the best (FVC + FEV\textsubscript{1}) was used for analysis. Results were entered into DATA-TRIEVE. The values obtained were related to those predicted for age, sex, and height, the prediction equations of Knudson \textit{et al} being used.\textsuperscript{15}

**STATISTICAL ANALYSIS**

This analysis was performed with the BMDP statistical package on a PDP 11/45 computer, or with the STAT program on a Radio Shack Model II computer.

**Results**

**SUBJECTS**

The subjects completing the questionnaire are described in table 1. The cystic fibrosis heterozygotes were older than the control parents. Although somewhat more of the controls had never smoked (p = 0·08), the mean number of pack years consumed by the two groups did not differ. Sex distribution was similar in the two groups. Analyses of questionnaire answers were performed for the entire group of subjects and for subgroups stratified by sex and smoking habits. Non-smokers or never-smokers were defined as those who had not smoked (pack years = 0).

**SYMPTOM COMPLAINTS**

Controls reported hay fever, dyspnoea, pneumonia, asthma, attacks of bronchitis, chronic bronchitis, and cough as frequently as cystic fibrosis heterozygotes (table 2).

Cystic fibrosis heterozygotes reported the presence of lung disease before the age of 16 twice as frequently as controls (table 2). These differences were significant in the initial analysis (p = 0·03, Mantel-Haenszel extension of the \(\chi^2\) test). The relative risk for history of lung disease before age 16 was 2·27 for the heterozygotes (95% confidence interval 1·05–5·0). Correction, however, for the fact that answers to multiple questions not included in the original hypothesis were

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Questionnaire study population: cystic fibrosis heterozygotes (HZ) and controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>HZ</td>
</tr>
<tr>
<td>Age (y): mean (SD)</td>
<td>41·2 (10·4)*</td>
</tr>
<tr>
<td>range</td>
<td>22–78</td>
</tr>
<tr>
<td>Male: No (%)</td>
<td>112 (36)</td>
</tr>
<tr>
<td>Never smokers: No (%)</td>
<td>129 (41)</td>
</tr>
<tr>
<td>Pack years: mean (SD)</td>
<td>11·0 (14·8)</td>
</tr>
</tbody>
</table>

*Groups differ: p < 0·001.
analysed (by the formula \( p = 1 - (1 - p)^{n} \)) reduced the p value to 0.24 for the difference between heterozygotes and controls in the answer to this question. Those who reported lung disease before age 16 had a lower FEV₁, forced mid expiratory flow (FEF₂₅₋₇₅), and FEV₁/forced vital capacity (FVC) ratio than those who did not when results were stratified for cigarette history, whether they were heterozygotes or controls.

Cystic fibrosis heterozygotes as a group reported wheezing somewhat more frequently than controls, although for most subgroups the difference did not achieve significance. The biggest difference between all heterozygotes and controls occurred in answer to question 10-2, “Do you ever wheeze apart from a cold?” (table 3). More smokers than non-smokers

Table 4  Pulmonary function in non-smokers (mean values with standard deviations in parentheses)

<table>
<thead>
<tr>
<th>Complain</th>
<th>Subjects</th>
<th>No (%) of subjects reporting symptoms</th>
<th>p indiv</th>
<th>p multiple samples</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Absent</td>
<td>Present</td>
<td></td>
</tr>
<tr>
<td>Hayfever</td>
<td>Heterozygotes</td>
<td>235 (75)</td>
<td>78 (25)</td>
<td>&gt;0.1</td>
</tr>
<tr>
<td></td>
<td>Controls</td>
<td>111 (78)</td>
<td>31 (22)</td>
<td></td>
</tr>
<tr>
<td>Attack bronchitis</td>
<td>Heterozygotes</td>
<td>225 (72)</td>
<td>87 (28)</td>
<td>&gt;0.1</td>
</tr>
<tr>
<td></td>
<td>Controls</td>
<td>104 (71)</td>
<td>42 (29)</td>
<td></td>
</tr>
<tr>
<td>Chronic bronchitis</td>
<td>Heterozygotes</td>
<td>295 (93)</td>
<td>23 (7)</td>
<td>&gt;0.1</td>
</tr>
<tr>
<td></td>
<td>Controls</td>
<td>152 (94)</td>
<td>10 (6)</td>
<td></td>
</tr>
<tr>
<td>Pneumonia</td>
<td>Heterozygotes</td>
<td>235 (75)</td>
<td>79 (25)</td>
<td>&gt;0.1</td>
</tr>
<tr>
<td></td>
<td>Controls</td>
<td>119 (74)</td>
<td>42 (26)</td>
<td></td>
</tr>
<tr>
<td>Cough</td>
<td>Heterozygotes</td>
<td>248 (76)</td>
<td>70 (22)</td>
<td>&gt;0.1</td>
</tr>
<tr>
<td></td>
<td>Controls</td>
<td>133 (82)</td>
<td>29 (18)</td>
<td></td>
</tr>
<tr>
<td>Dyspnœa</td>
<td>Heterozygotes</td>
<td>217 (69)</td>
<td>97 (31)</td>
<td>0.09</td>
</tr>
<tr>
<td></td>
<td>Controls</td>
<td>123 (76)</td>
<td>39 (24)</td>
<td></td>
</tr>
<tr>
<td>Asthma</td>
<td>Heterozygotes</td>
<td>294 (92)</td>
<td>24 (8)</td>
<td>&gt;0.1</td>
</tr>
<tr>
<td></td>
<td>Controls</td>
<td>153 (94)</td>
<td>9 (6)</td>
<td></td>
</tr>
<tr>
<td>Lung disease</td>
<td>Heterozygotes</td>
<td>274 (88)</td>
<td>38 (12)</td>
<td>0.03</td>
</tr>
<tr>
<td>before 16 y</td>
<td>Controls</td>
<td>153 (94)</td>
<td>9 (6)</td>
<td></td>
</tr>
</tbody>
</table>

*Interaction of complaint of wheezing and cystic fibrosis heterozygosity significant: p < 0.03 (ANOVA).
†Diagnosis of the child accounts for a significant portion of the variance: p < 0.04 (ANOVA).
FEF₂₅₋₇₅—mid forced expiratory flow; FVC—forced vital capacity.

Table 5  Pulmonary function in all subjects (mean values with standard deviations in parentheses)

<table>
<thead>
<tr>
<th>Wheeze (n = 209)</th>
<th>No wheeze (n = 206)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heterozygotes</td>
<td>97.9 (14.8)</td>
</tr>
<tr>
<td>Controls</td>
<td>102.1 (13.9)</td>
</tr>
<tr>
<td>Heterozygotes</td>
<td>98.9 (18.1)</td>
</tr>
<tr>
<td>Controls</td>
<td>97.9 (14.8)</td>
</tr>
<tr>
<td>Heterozygotes</td>
<td>65.8 (27.4)</td>
</tr>
<tr>
<td>Controls</td>
<td>69.1 (28.5)</td>
</tr>
<tr>
<td>Heterozygotes</td>
<td>77.3 (8.9)</td>
</tr>
<tr>
<td>Controls</td>
<td>78.8 (6.8)</td>
</tr>
</tbody>
</table>

*Both the diagnosis of the child and the complaint of wheezing contribute significantly (p < 0.05) to the variance. Abbreviations as in table 4.
Pulmonary abnormalities in obligate heterozygotes for cystic fibrosis

wheezed. Among those who had never smoked, 38% of heterozygotes but only 25% of controls had wheezed at some time (p < 0.05). Reports of wheeze among never-smokers were more common for both male and female heterozygotes and for all questions about wheeze (with a cold, apart from a cold, or most of the time) than among controls, but for the most part these differences did not reach significance. The age distribution of those who wheezed is statistically indistinguishable from the age distribution of those who deny wheezing for all subjects (cystic fibrosis heterozygotes and controls), for heterozygotes alone, and for heterozygotes and controls who never smoked. For example, wheezing was as common in heterozygote never-smokers over 50 years as in those under 50 (36% vs 38%).

Heterozygous never-smokers who wheezed had lower FEV1 and FEF25–75 (% predicted) values11 and a lower FEV1/FVC ratio than other non-smokers (table 4). The FEV1/FVC ratio was lower in heterozygotes than controls whether they wheezed or not, but for the flows the interaction of heterozygosity for cystic fibrosis and the complaint of wheezing was significant, indicating that the complaint of wheezing among non-smoking heterozygotes identifies a subpopulation with reduced airflow. Although the same trends were evident for the entire study group and for smokers and non-smokers, they did not achieve statistical significance (table 5).

Discussion

Parents of children with cystic fibrosis have increased airway reactivity to methacholine.9 Thirty per cent of heterozygotes but fewer than 5% of controls had their FEV1 reduced by 20% in response to less than 3 mg/ml (PC20FEV1 < 3 mg/ml).9 The degree of airway reactivity, however, was for the most part mild. Among 50 heterozygotes with no admitted lung disease and normal baseline pulmonary function, the lowest PC20FEV1 for methacholine was 0-6 mg/ml.9 This concentration, however, is only at the median PC20FEV1 for a group of very mildly affected symptomless, unmedicated asthmatic subjects studied in the same laboratory at the same time (0-78 mg/ml).16 For this reason, it may not be surprising that the excess prevalence of wheezing in the cystic fibrosis heterozygote population is small (table 3), and that there is no statistically significant increase in the prevalence of asthma (table 2). Nevertheless, the complaint of wheezing among heterozygotes seems to have some functional significance, for it identifies a subgroup with reduced airflow (table 4).

The excess prevalence of wheezing among heterozygous never-smokers could be due to overreporting of symptoms, to the cystic fibrosis gene, or to factors apart from the cystic fibrosis gene. Alternatively, a child with cystic fibrosis born into a household with parents who wheeze might be more likely to have the disease diagnosed, so the identification of parents by their relation to a child with known cystic fibrosis might bias the population of identified heterozygotes toward those who wheeze.

Cystic fibrosis heterozygotes might notice and report respiratory symptoms in themselves more readily because they look for them in their children. Most pulmonary symptoms, however, were not more prevalent in the cystic fibrosis heterozygotes (table 2). If cystic fibrosis heterozygotes overreport wheezing, then the pulmonary function of heterozygotes who complain of wheeze should be no worse than that of controls who wheeze, but in fact heterozygous never-smokers who wheezed had lower FEV1, FEF25–75, and FEV1/FVC than controls (table 4). Thus wheezing in cystic fibrosis heterozygotes is accompanied by objective pulmonary function changes. Overreporting of wheezing by heterozygotes thus seems unlikely.

Differences between the populations of heterozygotes and of controls unrelated to cystic fibrosis heterozygosity could produce more wheezing in heterozygotes. More heterozygotes than controls had smoked (table 1), but there is increased prevalence of wheezing even among those who had never smoked. Although the heterozygotes were older than controls (table 1), there was no difference in the reports of wheezing between cystic fibrosis heterozygote never-smokers above age 50 and up to 50, and the age distribution of cystic fibrosis heterozygotes who wheeze is the same as that of cystic fibrosis heterozygotes who deny wheeze, both for the entire group and for the never-smokers. Thus neither smoking nor age differences between cystic fibrosis heterozygotes and controls account for the increased prevalence of wheezing in cystic fibrosis heterozygotes.

The altered home environment produced by a child with cystic fibrosis might promote wheezing in the parents. For example, exposure of some parents to pancreatic extract powder by inhalation during the child’s infancy might sensitize the airway.17 Since very few parents currently handling pancreatic extract powder were studied, for this explanation to be valid we must postulate an effect that extends beyond the period of exposure to account for the group differences. Moreover, since the introduction of microencapsulated pancreatic enzyme preparations, exposure of parents to aerosolised proteolytic enzymes has been greatly reduced. In the present study younger cystic fibrosis heterozygotes have a prevalence of wheezing similar to that of older heterozygotes (who were more likely to have been exposed to powdered pancreatic enzymes). Cystic fibrosis mothers and fathers have a similar prevalence of
wheezing, though the mothers are more likely to have had intense exposure to the home environment and the pancreatic enzymes. Thus the patterns in the data do not implicate pancreatic enzyme powder exposure in the excess of wheezing among heterozygotes.

Parents of children with cystic fibrosis may be exposed more often to viral respiratory infections, which can lead to increased airway reactivity, or they may be more likely to become infected. Children with cystic fibrosis appear to acquire no more viral infections than other children of similar age, but the child with cystic fibrosis is more likely to develop symptoms. A child with symptoms might infect others in the household more readily. Or some combination of increased constitutional vulnerability and increased environmental exposure could operate to produce increased airway reactivity in cystic fibrosis heterozygotes.

Twice as many cystic fibrosis heterozygotes as controls, however, report lung disease before the age of 16 (table 2). If this can be confirmed in a study specifically aimed at testing this hypothesis, then some difference from the control population may occur in heterozygotes before exposure to the environment created by a child with cystic fibrosis. Other studies have shown that those who note lung disease early in life often are recalling childhood asthma, and in our study a positive correlation was noted between recall of lung disease before age 16 and asthma (r = 0.28 for non-smokers, p < 0.01). If a test to detect cystic fibrosis heterozygotes in the general population becomes available, the hypothesis that the home environment created by a child with cystic fibrosis contributes to respiratory symptoms can be tested more directly.

A familial tendency toward wheezing, as noted above, might make the child with cystic fibrosis more likely to be diagnosed, and in this case heterozygotes identified by their relation to a child with known cystic fibrosis (as they were for this study) may not be representative of all cystic fibrosis heterozygotes. If this is true, however, and if the children are more likely to be diagnosed because of increased severity of respiratory illness, then these children might also have reduced life expectancy and also be preferentially removed from the pool of families attending the clinic from which the study population was drawn. It is therefore difficult to predict the impact of any relationship between parental respiratory symptoms and disease severity in the children on the study population.

It is possible that cystic fibrosis heterozygotes, by virtue of their genetic make up, are more vulnerable to airway reactivity and wheezing. The gene for cystic fibrosis itself might exert a direct effect on the airway, or the cystic fibrosis gene (or another gene common in cystic fibrosis heterozygotes) might render its bearer vulnerable to environmental influences (for example, infection, environmental pollutants, or cigarette smoke) that may lead to airway reactivity.

Early investigations of the occurrence of lung disease in cystic fibrosis heterozygotes did not detect differences from controls, probably for several reasons. Most earlier studies were looking for confirmed diagnoses of diseases (such as asthma, emphysema, chronic bronchitis, often strictly defined) in a young to middle aged population, but lacked the statistical power to detect even a twofold increase in their prevalence. In our study, respiratory symptoms as well as diagnoses confirmed by physicians were recorded for more than twice as many subjects as in any of the previous studies. Standardised and validated questionnaire instruments were not used for some of the earlier studies. Moreover, smoking habits were often not considered in the analysis of earlier data, and so real differences between the experimental and control populations might be obscured (or spurious differences introduced).

In summary, pulmonary abnormalities can be revealed in cystic fibrosis heterozygotes by methacholine, and the major symptom of increased airway reactivity—wheezing—is somewhat more prevalent among heterozygotes than among controls. Moreover, among heterozygotes the complaint of wheezing appears to identify a subgroup with reduced airflow (tables 4–5). If these abnormalities arise from a single abnormal gene for cystic fibrosis, then we can speculate that (1) the basic defect in cystic fibrosis is expressed in the lungs of heterozygotes and should be demonstrable in the appropriate test system; (2) one gene for cystic fibrosis is sufficient to produce mild lung abnormalities in the absence of infection, so the lung disease in patients homozygous for the disease is not solely the consequence of chronic bacterial infection; (3) study of heterozygotes (in whom the secondary consequences of infection and structural damage will not obscure the initiating events) may elucidate the pathogenesis of the lung disease in cystic fibrosis. Whether or not the cystic fibrosis gene itself contributes to airway reactivity, a subpopulation of heterozygotes, those who wheeze, appear to be at risk for poorer pulmonary function or development and progression (with an appropriate promoter) of chronic obstructive lung disease. This hypothesis can be tested directly in a study of a still larger number of heterozygotes and controls.

The excellent assistance of Samuel Del Rio, Jane Root, and Gaye Paget is greatly appreciated. The assistance of the Cystic Fibrosis Center staff in recruiting and tracking subjects was invaluable. The pediatric cardiology division kindly allowed access to
Pulmonary abnormalities in obligate heterozygotes for cystic fibrosis

the parents of their patients. The help of Rachel Floyd in computerised data management and analysis is gratefully acknowledged. We thank Drs Pamela Byard and Naomi Breslau for helpful discussion of the statistics. This work was supported by grants from the Veterans Administration and the National Institutes of Health (HL28386, AM 27651), and PBD was a research associate of the Veterans Administration during most of the period of the study.

References

Pulmonary abnormalities in obligate heterozygotes for cystic fibrosis.

P B Davis and K Vargo

Thorax 1987 42: 120-125
doi: 10.1136/thx.42.2.120

Updated information and services can be found at:
http://thorax.bmj.com/content/42/2/120

Email alerting service

These include:

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/